RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Genomic study identifies MCU that regulates calcium transport into mitochondria

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

JPO issues patent to Silence Therapeutics' RNAi technology

JPO issues patent to Silence Therapeutics' RNAi technology

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Major pharmaceutical company, Access sign deal for RNAi therapeutics

Major pharmaceutical company, Access sign deal for RNAi therapeutics

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals to acquire Apthera

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Rxi's new RNAi preclinical data to be presented at Keystone conference

Rxi's new RNAi preclinical data to be presented at Keystone conference

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Alnylam to defend against Tekmira complaint

Alnylam to defend against Tekmira complaint

Global settlement agreement reached in Tuschl patents litigation

Global settlement agreement reached in Tuschl patents litigation

USPTO issues patent to Silence Therapeutics' siRNA technology

USPTO issues patent to Silence Therapeutics' siRNA technology